This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss
For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (1240)
-
April 02, 2026 | Comment Semaglutide patent expiry exposes global split on access, exclusivity
...and Drug Administration’s Orange Book of approved drugs, because they contained no active ingredient...
Sections: Intellectual Property
-
March 31, 2026 | Insight USPTO session features debates about PTAB value for life sciences patents
...and Drug Administration’s Orange Book and biologic patents making up about 5 percent of all petitions...
Sections: Intellectual Property
-
March 23, 2026 | Insight US FTC probes of research pipeline deals will continue, Guarnera says
Sections: Antitrust, Data Privacy and Security, DealRisk®, Mergers and Acquisitions, and Technology
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
View full search results
Already a subscriber? Click here to login